Encysive Pharma Shares Plummet

Max Re's audit committee starts review; DaimlerChrysler to boost spending on Smart brand; plus more stocks in the news Monday

Encysive Pharma (ENCY) shares plunged Monday after the company received an Approvable Letter requesting additional clinical trial work from the FDA for Thelin, which is under review for treatment of pulmonary arterial hypertension. Brean Murray, First Albany, and Needham each downgraded the shares.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.